<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247272</url>
  </required_header>
  <id_info>
    <org_study_id>R01-140</org_study_id>
    <nct_id>NCT01247272</nct_id>
  </id_info>
  <brief_title>90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the relative bioavailability (rate and extent of absorption) of 90 mg
      Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC
      WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy
      adult volunteers under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Fluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Fluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of Fluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Norfluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Informational comparison of Cmax values for the metabolite Norfluoxetine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of Norfluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Informational comparison of AUC0-t values for the metabolite Norfluoxetine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of Norfluoxetine.</measure>
    <time_frame>Blood samples collected over a 25 day period.</time_frame>
    <description>Bioequivalence based on Norfluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90 mg PROZAC WEEKLY® Capsules (Eli Lilly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg Fluoxetine Hydrochloride Capsules (Teva)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine Hydrochloride</intervention_name>
    <description>90 mg Capsules</description>
    <arm_group_label>Investigational Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROZAC WEEKLY®</intervention_name>
    <description>90 mg Capsules</description>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <other_name>Fluoxetine Hydrochloride (generic name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening Demographics: All volunteers selected for this study will be healthy men and
             women 18 years of age or older at the time of dosing. The weight range will not exceed
             + 15% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan
             Height and Weight Table or Desirable Weights for Women - 1983 Metropolitan Height and
             Weight Table.

          -  Screening Procedures: Each volunteer will complete the screening process within 28
             days prior to Period I dosing. Consent documents for both the screening evaluation and
             HIV antibody determination will be reviewed, discussed, and signed by each potential
             participant before full implementation of screening procedures.

          -  If female and:

               -  Of childbearing potential, is practicing an acceptable method of birth control
                  for the duration of the study as judged by the investigator(s), or

               -  Is postmenopausal for at least 1 year, or

               -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy).

        Exclusion Criteria:

          -  Volunteers with a recent history of drug or alcohol addiction or abuse.

          -  Volunteers with the presence of a clinically significant disorder involving the
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,
             endocrine, or neurologic system(s) or psychiatric disease (as determined by the
             clinical investigators).

          -  Volunteers whose clinical laboratory test values are outside the acceptable reference
             range and when confirmed on re-examination are deemed to be clinically significant.

          -  Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive
             HIV antibody screen.

          -  Volunteers demonstrating a positive drug abuse screen when screened for this study.

          -  Female volunteers demonstrating a positive pregnancy screen.

          -  Female volunteers who are currently breastfeeding.

          -  Volunteers with a history of allergic response(s) to fluoxetine or related drugs.

          -  Volunteers with a history of clinically significant allergies including drug
             allergies.

          -  Volunteers with a clinically significant illness during the 4 weeks prior to Period I
             dosing (as determined by the clinical investigators).

          -  Volunteers who currently use tobacco products.

          -  Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism
             in the 30 days prior to Period I dosing.

          -  Volunteers who report donating greater than 150 mL of blood within 30 days prior to
             Period I dosing. All subjects will be advised not to donate blood for 4 weeks after
             completing the study.

          -  Volunteers who have donated plasma within 14 days prior to Period I dosing. All
             subjects will be advised not to donate plasma for 4 weeks after completing the study.

          -  Volunteers who report receiving any investigational drug within 30 days prior to
             Period I dosing.

          -  Volunteers who report taking any systemic prescription medication in the 14 days prior
             to Period I dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Carlson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>January 24, 2011</results_first_submitted>
  <results_first_submitted_qc>January 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2011</results_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluoxetine Hydrochloride (Test) First</title>
          <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Prozac® Weekly (Reference) First</title>
          <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout of 28 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluoxetine Hydrochloride (Test) First</title>
          <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Prozac® Weekly (Reference) First</title>
          <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Fluoxetine.</title>
        <description>Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma).</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Fluoxetine.</title>
          <description>Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.17" spread="13.7"/>
                    <measurement group_id="O2" value="56.61" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>113.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>108.03</ci_lower_limit>
            <ci_upper_limit>118.96</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Fluoxetine.</title>
        <description>Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Fluoxetine.</title>
          <description>Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3625.61" spread="798"/>
                    <measurement group_id="O2" value="3363.94" spread="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>107.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.18</ci_lower_limit>
            <ci_upper_limit>113.69</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of Fluoxetine.</title>
        <description>Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Fluoxetine.</title>
          <description>Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3900.75" spread="1123"/>
                    <measurement group_id="O2" value="3645.90" spread="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>106.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.09</ci_lower_limit>
            <ci_upper_limit>112.12</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Norfluoxetine.</title>
        <description>Informational comparison of Cmax values for the metabolite Norfluoxetine.</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Norfluoxetine.</title>
          <description>Informational comparison of Cmax values for the metabolite Norfluoxetine.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.18" spread="14.2"/>
                    <measurement group_id="O2" value="33.00" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>103.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.54</ci_lower_limit>
            <ci_upper_limit>107.76</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t of Norfluoxetine.</title>
        <description>Informational comparison of AUC0-t values for the metabolite Norfluoxetine.</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Norfluoxetine.</title>
          <description>Informational comparison of AUC0-t values for the metabolite Norfluoxetine.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10996.87" spread="5041"/>
                    <measurement group_id="O2" value="10393.71" spread="5623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>105.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.66</ci_lower_limit>
            <ci_upper_limit>110.12</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf of Norfluoxetine.</title>
        <description>Bioequivalence based on Norfluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
        <time_frame>Blood samples collected over a 25 day period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine Hydrochloride (Test) First</title>
            <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
          </group>
          <group group_id="O2">
            <title>Prozac® Weekly (Reference) First</title>
            <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Norfluoxetine.</title>
          <description>Bioequivalence based on Norfluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12685.67" spread="6754"/>
                    <measurement group_id="O2" value="11986.28" spread="6321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>105.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.27</ci_lower_limit>
            <ci_upper_limit>110.61</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.</time_frame>
      <desc>Volunteers were monitored throughout the study for any adverse experiences. AEs were collected through both solicited and unsolicited methods. The volunteers were encouraged to report signs, symptoms, and any changes in health to the clinic staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluoxetine Hydrochloride (Test) First</title>
          <description>90 mg Fluoxetine Capsules test product dosed in first period followed by 90 mg Prozac® Weekly Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="E2">
          <title>Prozac® Weekly (Reference) First</title>
          <description>90 mg Prozac® Weekly Capsules reference product dosed in first period followed by 90 mg Fluoxetine Hydrochloride Capsules test product dosed in the second period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals, USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

